#2547 Humoral response to COVID vaccine and infection is intact during sibeprenlimab treatment of IgAN: data from the ENVISION trial
Kieran McCafferty(Queen Mary University of London), David Oldach(Visterra (United States)), Adrian Liew, Frank Engler(Certara (United States)), Kristin Follman(Certara (United States)), Mallory Shriver(University of Maryland, Baltimore), Yusuke Suzuki(Juntendo University), Marcela F. Pasetti(University of Maryland Global Campus), Jill Yarbrough(Visterra (United States)), Dana V. Rizk(University of Alabama at Birmingham), Mohit Mathur(John Hunter Hospital), Asher D. Schachter(Visterra (United States))
Cited by 1
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group
|Kidney International|2017|1.2k
Human Decidual Natural Killer Cells Are a Unique NK Cell Subset with Immunomodulatory Potential
|The Journal of Experimental Medicine|2003|897
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
|Kidney International|2021|809